Back

SGLT-2 inhibitors in the management of CVD and T2DM: brief update on results of the EMPA-REG OUTCOME trial.

28 August 2016 (15:50 - 16:00)
Organised by:
Congress Presentation Part of: SGLT2 inhibition in the management of CV risk & T2DM: ask the experts Diabetes management ESC Premium Access ESC Congress 2016

About the speaker

Photo
Professor Silvio Inzucchi

New Haven (United States of America)

2 More presentations in this session

Presentation thumbnail
Introduction - SGLT2 inhibition in the management of CV risk & T2DM: ask the experts.
Professor J. Deanfield (London, GB)
Presentation thumbnail
Interactive discussion: what are the implications of SGLT2 inhibition for CV risk reduction in a multi-risk patient population?
Professor J. Deanfield (London, GB) Professor S. Inzucchi (New Haven, US)

Access the full session

Session thumbnail
SGLT2 inhibition in the management of CV risk & T2DM: ask the experts

The Event

Event poster

ESC Congress 2016

28 August 2016 15:50 CET
You may be interested in
thumbnail
Congress Presentation
Impact of SGLT2 inhibitor on mortality and cardiovascular outcomes in patients with type 2 diabetes mellitus with left main or multivessel coronary artery disease
27 August 2022
thumbnail
Webinar
Early initiation of SGLT-2 inhibitors after acute decompensated heart failure
26 October 2022
thumbnail
Congress Presentation
Qualifying event proximity, cardiovascular risk, and benefit of empagliflozin in patients with type 2 diabetes and stable atherosclerosis in the EMPA-REG OUTCOME trial
31 August 2019
thumbnail
Congress Presentation
Divergent electrophysiologic safety profile of dapagliflozin and empagliflozin in a whole-heart model
27 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources